Cargando…
Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment
Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the number of individuals in Australia who would...
Autores principales: | Mitchell, Paul, Bressler, Neil, Doan, Quan V., Dolan, Chantal, Ferreira, Alberto, Osborne, Aaron, Rochtchina, Elena, Danese, Mark, Colman, Shoshana, Wong, Tien Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076243/ https://www.ncbi.nlm.nih.gov/pubmed/24979237 http://dx.doi.org/10.1371/journal.pone.0101072 |
Ejemplares similares
-
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008) -
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017) -
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017) -
Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)